X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-25 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $87.13 | -15,000 | 97,994 | -13% | -$1,307,000 | |||||
| M | 2026-06-25 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | COB, CEO, Interim CFO, 10% | S - Sale | $3.04 | -11,156 | 305,989 | -4% | -$33,919 | |||||
| M | 2026-06-24 | FTH | Faeth Therapeutics, Inc. | Stephenson Brian C | CFO | P - Purchase | $25.65 | +15,641 | 33,054 | +90% | +$401,269 | |||||
| DM | 2026-06-24 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | CEO | S - Sale+OE | $79.70 | -85,637 | 245,571 | -26% | -$6,825,524 | |||||
2026-06-25 | IONS | Ionis Pharmaceuticals Inc | Swayze Eric | EVP Research | S - Sale | $79.18 | -10,602 | 22,077 | -32% | -$839,492 | ||||||
| D | 2026-06-24 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $33.16 | -200,000 | 1,613,063 | -11% | -$6,631,268 | |||||
| DM | 2026-06-24 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale+OE | $85.78 | -26,283 | 60,137 | -30% | -$2,254,463 | |||||
| DM | 2026-06-24 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, MD | S - Sale+OE | $50.02 | -35,412 | 519,227 | -6% | -$1,771,174 | |||||
| D | 2026-06-24 | PRAX | Praxis Precision Medicines, Inc. | Desimone Jill | Dir | S - Sale+OE | $311.32 | -11,600 | 2,337 | -83% | -$3,611,335 | |||||
2026-06-25 | VTRS | Viatris Inc | Campbell Paul | See Remarks | S - Sale | $16.17 | -50,076 | 316,530 | -14% | -$809,784 | ||||||
| D | 2026-06-25 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $550.40 | -9,500 | 668,728 | -1% | -$5,228,773 | |||||
2026-06-25 | DYN | Dyne Therapeutics, Inc. | Lucera Erick | CFO | S - Sale | $20.37 | -2,362 | 121,563 | -2% | -$48,114 | ||||||
| D | 2026-06-25 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $103.32 | -21,398 | 492,841 | -4% | -$2,210,763 | |||||
| M | 2026-06-23 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Dir | S - Sale | $21.09 | -267,760 | 1,089,006 | -20% | -$5,646,497 | |||||
2026-06-23 | ADTX | Aditxt, Inc. | Takeover Time 2026 LLC | 10% | S - Sale | $0.02 | -3,420,439 | 0 | -100% | -$68,409 | ||||||
2026-06-25 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale | $20.00 | -5,394 | 115,005 | -4% | -$107,880 | ||||||
| D | 2026-06-25 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $20.06 | -28,935 | 13,579 | -68% | -$580,506 | |||||
| D | 2026-06-23 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $18.00 | -1,450 | 51,776 | -3% | -$26,100 | |||||
2026-06-23 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $276.26 | -1,292 | 1,290,089 | 0% | -$356,927 | ||||||
2026-06-23 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale | $273.78 | -3,410 | 51,637,304 | 0% | -$933,592 | ||||||
2026-06-23 | ONC | Beone Medicines Ltd. | Wang Lai | Pres, Global Head of R, D | S - Sale | $276.74 | -1,068 | 2,282,969 | 0% | -$295,553 | ||||||
2026-06-24 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $55.18 | -9,098 | 9,099 | -50% | -$502,067 | ||||||
2026-06-23 | RPRX | Royalty Pharma Plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $54.40 | -150,000 | 629,399 | -19% | -$8,159,277 | ||||||
| D | 2026-06-24 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $548.69 | -9,500 | 668,728 | -1% | -$5,212,520 | |||||
2026-06-24 | LITS | Lite Strategy, Inc. | Flynn James P | Dir | P - Purchase | $0.86 | +25,000 | 125,000 | +25% | +$21,388 | ||||||
| D | 2026-06-23 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Dir | S - Sale+OE | $117.94 | -9,000 | 7,825 | -53% | -$1,061,460 | |||||
| D | 2026-06-23 | GALT | Galectin Therapeutics Inc | Jamil Khurram | Chief Medical Officer | S - Sale+OE | $3.14 | -7,557 | 0 | -100% | -$23,729 | |||||
2026-06-22 | KARD | Kardigan, Inc. | Hrtg Gpe, LLC | 10% | P - Purchase | $16.00 | +3,125,000 | 16,917,034 | +23% | +$50,000,000 | ||||||
| M | 2026-06-24 | OTLC | Oncotelic Therapeutics, Inc. | Trieu Vuong | COB, CEO, 10% | P - Purchase | $0.05 | +255,000 | 117,347,232 | 0% | +$11,475 | |||||
| D | 2026-06-22 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale+OE | $72.66 | -9,700 | 54,324 | -15% | -$704,795 | |||||
| M | 2026-06-22 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $14.34 | -171,405 | 169,556 | -50% | -$2,458,582 | |||||
| D | 2026-06-22 | EVMN | Evommune, Inc. | Drew Janice Suzann | Chief of Dev. Operations | S - Sale+OE | $22.63 | -20,000 | 67,794 | -23% | -$452,600 | |||||
| D | 2026-06-22 | EVMN | Evommune, Inc. | Patel Jeegar Pravinkumar | Chief Scientific Officer | S - Sale+OE | $22.50 | -1,488 | 46,403 | -3% | -$33,480 | |||||
| DM | 2026-06-22 | CAPR | Capricor Therapeutics, Inc. | Krasney Karen | EVP, GC | S - Sale+OE | $30.00 | -900 | 30,547 | -3% | -$27,000 | |||||
| DM | 2026-06-22 | CAPR | Capricor Therapeutics, Inc. | Bergmann Anthony | CFO | S - Sale+OE | $30.00 | -900 | 11,223 | -7% | -$27,000 | |||||
2026-06-22 | EVMN | Evommune, Inc. | Pena Luis C. | Pres, CEO | S - Sale | $22.71 | -7,438 | 630,458 | -1% | -$168,917 | ||||||
2026-06-22 | OKUR | Onkure Therapeutics, Inc. | Saccomano Nicholas A | Pres, CEO | S - Sale | $4.40 | -86 | 11,247 | -1% | -$378 | ||||||
2026-06-22 | OKUR | Onkure Therapeutics, Inc. | Leverone Jason A. | CFO | S - Sale | $4.40 | -303 | 18,802 | -2% | -$1,332 | ||||||
| D | 2026-06-22 | SEPN | Septerna, Inc. | Long Daniel D. | SVP, Drug Discovery | S - Sale+OE | $35.51 | -15,000 | 96,412 | -13% | -$532,582 | |||||
2026-06-22 | ELVN | Enliven Therapeutics, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $45.36 | -860,123 | 6,555,102 | -12% | -$39,014,046 | ||||||
| D | 2026-06-23 | NUVB | Nuvation Bio Inc. | Markel Stacy | Chief People Officer | S - Sale+OE | $6.03 | -125,000 | 32,591 | -79% | -$753,188 | |||||
| D | 2026-06-23 | NUVB | Nuvation Bio Inc. | Wentworth Kerry | Chief Regulatory Officer | S - Sale+OE | $6.02 | -63,000 | 53,000 | -54% | -$379,191 | |||||
| D | 2026-06-23 | NUVB | Nuvation Bio Inc. | Sauvage Philippe | CFO | S - Sale+OE | $6.01 | -47,668 | 12,673 | -79% | -$286,370 | |||||
| M | 2026-06-22 | FTH | Faeth Therapeutics, Inc. | Stephenson Brian C | CFO | P - Purchase | $23.31 | +17,413 | 17,413 | New | +$405,921 | |||||
| D | 2026-06-22 | FTH | Faeth Therapeutics, Inc. | Parikh Anand Kiran | Pres, CEO | P - Purchase | $19.76 | +2,806 | 817,699 | 0% | +$55,447 | |||||
| DM | 2026-06-23 | BBIO | Bridgebio Pharma, Inc. | Cook Jennifer E. | Dir | S - Sale+OE | $69.92 | -39,363 | 8,383 | -82% | -$2,752,270 | |||||
| DM | 2026-06-22 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | S - Sale+OE | $68.25 | -5,004 | 9,657 | -34% | -$341,524 | |||||
| M | 2026-06-22 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Pres | S - Sale | $27.92 | -31,431 | 1,269,100 | -2% | -$877,501 | |||||
2026-06-24 | ARVN | Arvinas, Inc. | Saik Andrew | CFO | S - Sale | $8.16 | -5,696 | 187,432 | -3% | -$46,474 | ||||||
| D | 2026-06-22 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale+OE | $80.90 | -23,749 | 62,874 | -27% | -$1,921,378 | |||||
| M | 2026-06-22 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | COB, CEO, Interim CFO, 10% | S - Sale | $3.48 | -11,444 | 317,145 | -3% | -$39,829 | |||||
2026-06-18 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | P - Purchase | $0.01 | +7,340,178 | 0 | -100% | +$95,422 | ||||||
2026-06-22 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | S - Sale | $0.02 | -5,120,480 | 0 | -100% | -$92,169 | ||||||
2026-06-23 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale | $37.93 | -18,500 | 420,274 | -4% | -$701,769 | ||||||
2026-06-22 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $4.18 | -20,871 | 591,242 | -3% | -$87,241 | ||||||
2026-06-22 | VSTM | Verastem, Inc. | Calkins Daniel | CFO | S - Sale | $4.18 | -4,089 | 117,238 | -3% | -$17,089 | ||||||
| D | 2026-06-23 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $543.96 | -9,500 | 668,728 | -1% | -$5,167,571 | |||||
2026-06-22 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $75.74 | -100,000 | 951,667 | -10% | -$7,573,704 | ||||||
| M | 2026-06-22 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Dir | S - Sale | $20.70 | -263,962 | 3,848,256 | -6% | -$5,464,611 | |||||
2026-06-24 | CNTA | Centessa Pharmaceuticals Plc | Medicxi Ventures Management (Jersey) Ltd | 10% | S - Sale | $0.00 | -19,963,157 | 0 | -100% | -$0 | ||||||
2026-06-24 | CNTA | Centessa Pharmaceuticals Plc | Index Ventures Life VI (Jersey) L.P. | 10% | S - Sale | $0.00 | -9,961,789 | 0 | -100% | -$0 | ||||||
2026-06-22 | KARD | Kardigan, Inc. | Berns Paul L | Dir, 10% | P - Purchase | $16.00 | +1,250,000 | 15,062,741 | +9% | +$20,000,000 | ||||||
2026-06-22 | KARD | Kardigan, Inc. | Arch Venture Partners Xiii, LLC | Dir, 10% | P - Purchase | $16.00 | +1,250,000 | 15,042,035 | +9% | +$20,000,000 | ||||||
| D | 2026-06-22 | RYTM | Rhythm Pharmaceuticals, Inc. | Tetrault Lynn A. | Dir | S - Sale+OE | $100.32 | -37,000 | 7,000 | -84% | -$3,711,896 | |||||
2026-06-22 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $95.82 | -1,806 | 37,648 | -5% | -$173,051 | ||||||
2026-06-23 | IMRX | Immuneering Corp | Zeskind Benjamin J. | Pres, CEO | P - Purchase | $4.56 | +2,400 | 3,210,179 | 0% | +$10,948 | ||||||
| D | 2026-06-22 | NAMS | Newamsterdam Pharma Co N.V. | Kooij Louise Frederika | Chief Accounting Officer | S - Sale+OE | $30.20 | -40,000 | 24,353 | -62% | -$1,208,159 | |||||
2026-06-22 | ZLAB | Zai Lab Ltd | Lis William | Dir | S - Sale | $18.09 | -7,040 | 50,437 | -12% | -$127,354 | ||||||
2026-06-22 | RIGL | Rigel Pharmaceuticals Inc | Ali-Jackson Kamil | Dir | S - Sale | $35.00 | -2,500 | 10,125 | -20% | -$87,500 | ||||||
| D | 2026-06-23 | AQST | Aquestive Therapeutics, Inc. | Krop Julie | Dir | S - Sale+OE | $5.02 | -25,000 | 0 | -100% | -$125,393 | |||||
2026-06-22 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale | $35.01 | -10,000 | 129,763 | -7% | -$350,100 | ||||||
| D | 2026-06-22 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $537.74 | -9,500 | 668,728 | -1% | -$5,108,527 | |||||
2026-06-22 | SPTX | Seaport Therapeutics, Inc. | Hombach Robert J. | Dir | P - Purchase | $18.14 | +13,000 | 13,000 | New | +$235,768 | ||||||
| D | 2026-06-23 | SYRE | Spyre Therapeutics, Inc. | Fairmount Funds Management LLC | Dir | S - Sale+OE | $85.31 | -4,684,781 | 812,076 | -85% | -$399,658,667 | |||||
2026-06-22 | SYRE | Spyre Therapeutics, Inc. | Henderson Michael Thomas | Dir | S - Sale | $100.00 | -20,000 | 68,606 | -23% | -$2,000,000 | ||||||
2026-06-18 | CDT | Cdt Equity Inc. | Taylor Mark Andrew | 10% | S - Sale | $1.42 | -2,068,000 | 0 | -100% | -$2,945,586 | ||||||
| D | 2026-06-23 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $79.51 | -3,500 | 153,902 | -2% | -$278,285 | |||||
| D | 2026-06-18 | IRON | Disc Medicine, Inc. | Khara Rahul | GC | S - Sale+OE | $70.22 | -7,500 | 52,173 | -13% | -$526,661 | |||||
| D | 2026-06-18 | IRON | Disc Medicine, Inc. | Quisel John D | CEO | S - Sale+OE | $70.21 | -34,000 | 226,064 | -13% | -$2,387,296 | |||||
| D | 2026-06-18 | PHVS | Pharvaris N.V. | Lu Peng | Chief Medical Officer | S - Sale+OE | $34.00 | -300 | 65,631 | 0% | -$10,200 | |||||
| D | 2026-03-24 | TPST | Tempest Therapeutics, Inc. | Angel Matthew | CEO, Pres, 10% | P - Purchase | $2.16 | +231,482 | 231,482 | New | +$500,001 | |||||
| D | 2026-06-22 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $538.15 | -8,750 | 18,876 | -32% | -$4,708,786 | |||||
| D | 2026-06-22 | ZVRA | Zevra Therapeutics, Inc. | Thompson Rahsaan | Chief Legal, Compliance | S - Sale+OE | $12.68 | -34,557 | 80,235 | -30% | -$438,304 | |||||
2026-06-18 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $462.17 | -1,020 | 15,933 | -6% | -$471,413 | ||||||
2026-06-22 | CBIO | Crescent Biopharma, Inc. | Lynch Ryan | See Remarks | S - Sale | $17.99 | -465 | 13,871 | -3% | -$8,365 | ||||||
2026-06-22 | CBIO | Crescent Biopharma, Inc. | Pinkas Jan | Chief Scientific Officer | S - Sale | $17.99 | -1,288 | 22,239 | -5% | -$23,171 | ||||||
2026-06-22 | CBIO | Crescent Biopharma, Inc. | Scalzo Richard William | CFO | S - Sale | $17.99 | -1,112 | 20,298 | -5% | -$20,005 | ||||||
2026-06-22 | CBIO | Crescent Biopharma, Inc. | Bispham Barbara Harlin | See Remarks | S - Sale | $17.99 | -1,218 | 19,330 | -6% | -$21,912 | ||||||
2026-06-22 | CBIO | Crescent Biopharma, Inc. | Im Ellie Eunkyung | Chief Medical Officer | S - Sale | $17.99 | -1,219 | 22,069 | -5% | -$21,930 | ||||||
2026-06-22 | CBIO | Crescent Biopharma, Inc. | McNeill Jonathan | Pres, COO | S - Sale | $17.99 | -20,549 | 139,158 | -13% | -$369,677 | ||||||
2026-06-22 | CBIO | Crescent Biopharma, Inc. | Brumm Joshua T | CEO | S - Sale | $17.99 | -42,305 | 281,212 | -13% | -$761,067 | ||||||
2026-06-22 | MLTX | Moonlake Immunotherapeutics | Bodenstedt Matthias | CFO | S - Sale | $22.04 | -39,120 | 1,115,435 | -3% | -$862,205 | ||||||
| D | 2026-06-22 | SVRA | Savara Inc | Lowrance David L | CFO | S - Sale+OE | $5.68 | -394,528 | 536,032 | -42% | -$2,241,432 | |||||
2026-06-22 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale | $80.95 | -1,587 | 15,312 | -9% | -$128,468 | ||||||
| D | 2026-05-22 | SER | Serina Therapeutics, Inc. | Venkatesan Jay | Dir | P - Purchase | $1.78 | +589 | 232,294 | 0% | +$1,048 | |||||
2026-06-17 | HOWL | Werewolf Therapeutics, Inc. | Ra Capital Management, L.P. | 10% | S - Sale | $0.35 | -416,911 | 303,719 | -58% | -$145,919 | ||||||
2026-06-18 | KURA | Kura Oncology, Inc. | Leoni Mollie | Chief Medical Officer | S - Sale | $9.82 | -84,929 | 182,345 | -32% | -$834,283 | ||||||
| D | 2026-06-18 | NBP | Novabridge Biosciences | Dennis Phillip Andrew | Chief Medical Officer | S - Sale+OE | $0.66 | -8,494 | 157,941 | -5% | -$5,606 | |||||
| D | 2026-06-17 | PTCT | Ptc Therapeutics, Inc. | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | S - Sale+OE | $75.56 | -19,686 | 70,199 | -22% | -$1,487,474 | |||||
| D | 2026-06-17 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $78.65 | -10,462 | 105,272 | -9% | -$822,868 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |